This CPB has been revised to (i) state that goliumumab is considered medically necessary for active psoriatic arthritis when used alone or in combination with methotrexate in members who have an inadequate response to two or more non-biologic disease-modifying anti-rheumatic drugs (DMARDs), and (ii) delete DMARDs as a criterion for the use of golimumab for the treatment of active ankylosing spondylitis.